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Interest is increasing regarding use of Cannabidiol (CBD) in companion animals due
to anecdotal evidence of beneficial behavioral and health effects. The purpose of
this investigation was to evaluate the influence of CBD on behavioral responses to
fear-inducing stimuli in dogs. Sixteen dogs (18.1 ± 0.2 kg) were utilized in a replicated 4 ×
4 Latin square design experiment with treatments arranged in a 2 × 2 factorial, consisting
of control, 25 mg CBD, trazodone (100 mg for 10–20 kg BW, 200 mg for 20.1–40 kg BW),
and the combination of CBD and trazodone. A fireworks model of noise-induced fear was
used to assess CBD effectiveness after 7 d of supplementation. Each test lasted a total of
6 min and consisted of a 3 min environmental habituation phase with no noise and a 3 min
noise phase with a fireworks track. Plasma was collected 1 h before, immediately after,
and 1 h following testing for cortisol analysis. Behaviors in each 3 min block were video
recorded, and heart rate (HR) sensors were fitted for collection of HR and HR variability
parameters. Research personnel administering treats and analyzing behavioral data were
blinded as to the treatments administered. Data were tested for normality using the
UNIVARIATE procedure in SAS, then differences examined using the MIXED procedure
with fixed effects of treatment, period, time, and treatment x time interaction. Inactivity
duration and HR increased during the first minute of the fireworks track compared with
1 min prior (P < 0.001 and P = 0.011, respectively), indicating the fireworks model
successfully generated a fear response. Trazodone lowered plasma cortisol (P < 0.001),
which was unaffected by CBD (P = 0.104) or the combination with CBD (P = 0.238).
Neither CBD nor trazodone affected the duration of inactivity (P = 0.918 and 0.329,
respectively). Trazodone increased time spent with tail relaxed (P = 0.001). CBD tended
to increase HR (P = 0.093) and decreased the peak of low- and high-frequency bands
(LF and HF, P = 0.011 and 0.022, respectively). These results do not support an anxiolytic
effect of CBD in dogs given 1.4 mg CBD/kg BW/d.
Keywords: cannabidiol, cbd, canine, behavior, fear, fireworks
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INTRODUCTION

evaluate the influence of CBD on behavioral responses to fearinducing stimuli in dogs, with the underlying hypothesis was
that CBD would reduce fearful and anxious responses. This
hypothesis was tested using a fireworks model of noise-induced
fear and anxiety in which the effectiveness of CBD was assessed
by comparing CBD to both a positive and negative control and to
the combination of CBD with the positive control. All treatments
were expected to reduce fearful and anxious responses compared
to the negative control.

Noise aversion or reactivity is one of the most common fearful
behaviors in dogs, with 40 to 50% of dogs demonstrating at
least one fearful behavior in response to noise exposure (1,
2). There is, however, considerable variation in the behavioral
responses to noise. Some dogs will reduce activity while others
become hyperactive. Some behavioral changes, such as panting
and hiding, are mild, while others, like destructiveness and selftrauma, are more extreme and potentially hazardous to the health
and well-being of both dog and owner (3). Such extreme and
detrimental; stress associated with fear reduces overall health and
lifespan (4, 5).
Despite the prevalence of noise aversion behaviors in dogs,
they frequently go untreated with less than one-third of dog
owners reporting that they would seek advice for the treatment
of noise aversion (1). Potential treatment regimens for various
noise aversion behaviors include systematic desensitization
with a CD-based training system and administration of
medications or natural products (3). There are several commonly
prescribed drugs for the treatment of canine behavior disorders
associated with fear and anxiety, including benzodiazepines,
selective serotonin reuptake inhibitors, and tricyclic antidepressants (6, 7). However, some owners may be hesitant to
administer such medications, whether due to the possibility
of undesirable side effects, personal bias against drug use, or
cost. This has led to increased interest in the use of natural
extract products to alter fearful behaviors, like dog-appeasing
pheromones or oral supplementations such as L-theanine, a
tryptic hydrolysate of milk protein and fish hydrolysate (8–
12). Additionally, there has been renewed interest in the
use of cannabinoids, cannabidiol (CBD) in particular, to
regulate anxiety disorders in both humans and companion
animals (13).
Cannabidiol is one of over 90 cannabinoids produced
by Cannabis sativa and has been proposed to exert several
beneficial effects, including acting as an anti-inflammatory,
immunomodulatory, and anxiolytic agent (14–16). But unlike
19 -tetrahydrocannabinol (THC), the other major cannabinoid
produced by C. sativa that is toxic to dogs, CBD does not
produce psychoactive effects due to its low affinity for the CB1
receptor (17). The potential anxiolytic effects of CBD have been
attributed to several mechanisms, including its activation of 5HT1A receptors and its ability to indirectly activate cannabinoid
receptors by inhibiting the metabolism of the endocannabinoid
anandamide (18, 19). This has produced great interest in using
CBD as a potential alternative to conventional therapies to reduce
anxiety. While there is considerable work examining its use as an
anxiolytic in human and rodent models [reviewed extensively in
(19)], this effect has yet to be examined in a canine model. But
despite the lack of evidence, canine anxiety, and noise aversion
are some of the most common reasons that pet owners seek
information on and administer CBD to their pets (20).
As interest in, and use of, CBD in companion animals
continues to increase, there is a critical need for research
evaluating both the safety and effectiveness of CBD use for canine
anxiety. Therefore, the objective of the current study was to
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MATERIALS AND METHODS
This study was reviewed and approved by the Lincoln Memorial
University (LMU) institutional animal care and use committee
(protocol number: 1811-RES) prior to the start of the study.
All housing and husbandry received were in accordance with
the Animal Welfare Act, the Guide for the Care and Use of
Laboratory Animals (8th ed.), and all applicable LMU SOPs.

Subjects and Housing
Twenty-four intact, adult dogs (12 male, 12 female; 1 to 5
years old; 17.7 ± 3.9 kg) of various mixed breeds, including
Cur, Lab, Hound, Boxer, Shepherd, Dane, Schipperkee, Springer
Spaniel, and Pit mixes were received from a local shelter for
inclusion in this study. The shelter was asked to provide dogs
weighing 16 ± 4 kg. Additionally, the shelter was informed and
gave consent for the use of the dogs for research purposes
prior to their arrival. Prior to beginning the experiment, each
dog had a complete blood count (CBC), and serum chemistry
analysis (IDEXX Laboratories, Inc., Westbrook, ME) performed,
along with physical evaluation by a veterinarian and a fecal
examination to rule out any underlying disease that might
preclude enrollment. Dogs were excluded if they demonstrated
serious behavioral issues, such as human aggression that would
endanger research personnel, were severely emaciated, classified
as a body condition score < 2 on a 5-point scale (where one
is emaciated and five is obese), or if their initial evaluations
revealed an underlying disease that required more than routine
treatments (such as heartworm positive dogs). Two dogs were
excluded from the experiment due to positive heartworm tests
and 4 additional dogs were excluded due to other health or
behavioral concerns. Dogs were individually housed in 1.2 ×
1.8 m cages within one of two dog kennels at the LMU DeBusk
Veterinary Teaching Center. Dogs were stratified by sex and
evenly distributed between the two kennels.

Diets and Treatments
Dogs were fed Purina Pro Plan EN Gastroenteric Dry Dog
Food (Nestle Purina Inc., St. Louis, MO) to meet the daily
metabolizable energy requirements of intact adult dogs at
maintenance, calculated as (70 ∗ BW0.75 ) ∗ 1.8 and split into two
meals fed at ∼0,730 and 1,830 h each day. Dogs were weighed and
body condition scored (5-point scale) weekly and diets adjusted
accordingly. Treatments were arranged in a 2 × 2 factorial and
consisted of (1) control (placebo treats), (2) 1.4 mg CBD/kg
BW/d, (3) Trazodone + 0 mg CBD, and (4) 1.4 mg CBD/kg BW/d
+ Trazodone. Trazodone was dosed at 100 mg for dogs weighing
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10.0–20.0 kg and at 200 mg for dogs weighing 20.1–40 kg as
recommended by the veterinarian and based on previous work
(21). Because trazodone does not require an extensive adaptation
period, trazodone tablets were dosed via a Pill Pocket (Mars
Petcare US, Franklin, TN) the evening prior and morning of the
behavioral assessment.
The CBD was a constituent of a proprietary industrial hemp
extract (AgTech Scientific, Paris, KY) that was incorporated into
treats and administered in the form of two treats daily, with each
treat containing half the daily dose. Groups not receiving CBD
treatment received control treats (0 mg CBD). Both control and
CBD treats were composed of the following ingredients: chicken,
chicken liver, Asian carp, catfish, and in the case of the CBD
treats, industrial hemp extract. Dosage of CBD was selected based
on a preliminary palatability study that assessed increasing levels
of CBD inclusion on food and treat consumption (unpublished).
Treats were formulated to include CBD at a dose of 2 mg/kg
BW/d based on an estimation that dogs would weigh an average
of 16 kg. However, based on the mean weight of dogs included on
the study, actual dosage of CBD was 1.4 mg/kg BW/d.
Treats were offered solely as a reward upon kennel re-entry
following twice daily exercise at ∼0,700 and 1,800 h each day.
Trazodone tablets hidden in Pill Pockets were administered
at ∼1,830 h the evening before and 1,000 h the morning of
each noise-induced fear response test. Empty Pill Pockets were
administered to the control and CBD treatment groups on those
days to ensure that research personnel administering the treats
were blinded as to the treatments administered.

TABLE 1 | Schedule of events.
Key event

−7 to −6

Animal intake, physical exam, and bloodwork
(CBC/serum chemistry)

−5 to −3

Acclimation to diet, daily routine, and testing room

−2

Open field test

−1

Baseline fireworks test

1 to 4

Start of treatment 1 (Squares 1–4 started on
consecutive days)

7 to 10

Period 1 Fireworks Test, start of treatment 2 evening
after test

14 to 17

Period 2 Fireworks Test, start of treatment 3 evening
after test

21 to 24

Period 3 Fireworks Test, start of treatment 4 evening
after test

28 to 31

Period 4 Fireworks Test

baseline fireworks test was conducted (described below). Both
the open field test and baseline fireworks test were used solely
to select dogs for inclusion in the study. Dogs not exhibiting at
least one behavioral change between the open field test and the
fireworks test; behaviors such as cowering, shaking, vocalization,
destructiveness, or tail tucking, were excluded from the study.
Dogs included in the study spent 6 min in the test room every
day throughout the experiment to eliminate the possibility of
behavioral changes due to the novel environment of the test
room. In order to acclimate dogs to the testing procedure, heart
rate monitor bands were placed on the dogs for each days
adaptation to the test room. Additionally, blood draws were
simulated on non-testing days by restraining dogs and holding
off cephalic and jugular veins prior to placing them in the testing
room. The fireworks test was conducted on the last day of each
7-d period (Table 1).

Testing Room and Equipment
The testing room was an ∼2.72 × 3.38 m isolation room located
on the opposite side of the building relative to where dogs were
housed. The room contained a wall-mounted table and cabinets,
a set of closed metal kennels, and a cloth dog bed. The dogs
could interact with these objects, but none obstructed the dogs
from view of the cameras. Two cameras (Model BRC-Z700,
Sony Co., New York, NY and Model B07DQPS3KY, QallExpress
International, China) were secured on opposite sides of the
room near the ceiling–∼2 m from the floor—to ensure the dogs
would be within sight at all times. Dogs were isolated in the
testing room; handlers monitored the dogs from the adjacent
room via the cameras and could not be seen by dogs. Two
Bluetooth speakers (Bose Co., Framingham, MA) were placed
on opposite sides of the room near the cameras to create a
surround-sound effect during the noise tests. Between each dog’s
test, the room was cleaned with RescueTM Concentrate (Virox
Animal Health, Oakville, ON, Canada), an accelerated hydrogen
peroxide-based disinfectant.

Open Field and Fireworks Tests
A fireworks model of noise-induced fear and anxiety was utilized
to assess the effectiveness of the treatments. All dogs received
from the shelter (n = 24) received 1 open field test and 1 baseline
fireworks test. All dogs included on the study (n = 16) also
received 1 fireworks test per 7-d period (5 total fireworks tests),
each lasting 6 min. During the open field test, the dogs were
placed in the testing room and their behavior was recorded in
two 3-min blocks where no fireworks track was played in order
to assess baseline behavior of dogs in the testing room. During
the fireworks tests, the first 3-min block was the same as the
open field test where no noise was played (Pre-Noise), and the
fireworks track was played over a stereo speaker system (mean)
during the second 3-min block (Noise).
In previous work using this model, a thunderstorm track was
utilized to test the noise-induced fear response in dogs (9, 22).
However, a fireworks video (https://www.youtube.com/watch?v=
5eLcHJLDlI8) was used because according to Blackwell et al.
(1) a larger percentage of dogs respond to fireworks than to
thunderstorms. This noise-induced fear response test used in this

Acclimation
After intake and entrance into the study, all dogs were adapted
to their environment, diet, daily routine, and the testing room
for 3 d (Table 1), in which the dogs spent 6 min in the testing
room where behavior was monitored, but not scored. A baseline
open field test followed the 3-d adaptation, where dogs were
placed in the testing room, behavior was scored, but no noise
track was played (described below). The next day, a 6-min
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study was a modified version of the one developed and validated
by Araujo et al. (22). They utilized a 9-min test that included
“before,” “during,” and “after” thunderstorm time points. Because
they saw no behavioral differences (i.e., near door duration,
inactivity duration) between the “during” and “after” thunder
time points, the test for this study was shortened to 6 min, ending
immediately after the fireworks track (Noise time point) ended.
This allowed for the immediate post-test blood sample collection
to be obtained more quickly after the fireworks test. The mean
of 90 dB was selected based on previous work (9, 22) that were
both successful in generating a response using equal or lesser
decibel thunderstorm track. Behaviors in each 3-min time block
were recorded and analyzed as separate time points (Pre-Noise
and Noise).

TABLE 2 | Definition of heart rate (HR) and heart rate variability (HRV) parameters.

Experimental Design
Sixteen dogs were included in this study (7 male, 9 female; 1
to 4 years old, mean BW 18.1 ± 0.2 kg). Dogs were selected
based on their behavioral response to the baseline noise-induced
fear test (described above), in which behaviors such as cowering,
shaking, vocalization, destructiveness, and tucking tail upon the
start of the fireworks track indicated the dog was reactive to noise.
These behaviors were selected as they have been previously used
to assess noise reactivity (9, 12, 23). Included dogs were then
arranged in a replicated 4 × 4 Latin Square design experiment
in which dogs within each square (4 dogs per square) were
randomly assigned to receive one of the four treatments each
week (Periods 1–4). Each square was tested on successive days
for scheduling purposes. Dogs received each treatment for a 7d period prior to each of the noise-induced fear response tests
(Table 1).
On testing days, all experimental procedures started at 1,200 h.
CBD treats were administered ∼4 to 6 hours prior to the test, and
the morning dose of trazodone was administered ∼2 to 4 h prior
to the test. Dogs received the test at the same time each week.
No washout period was included between treatment periods. At
the time of the completion of this study (July 2018), there was
little literature available on the pharmacokinetics of oral CBD
administration. Samara et al. (24) reported that the half-life of
IV CBD administration was 6 to 9 h but had no estimate for
an oral dose. For a similar dose of trazodone, Jay et al. (21)
reported a mean half-life of elimination of 166 min. From these
half-lives, it was decided that the 7-d treatment period would be
sufficient to allow for elimination of previous treatments prior
to the next test while also allowing for acclimation to the next
treatment. Additionally, time constraints on the availability of the
kennels in which the dogs were housed prevented the inclusion of
washout periods.
Because of scheduling constraints, the test started as soon
as the dogs entered the testing room on testing days. This did
not allow for either HRV or behavior to return to normal after
movement from kennel to testing room. To account for this,
only data from the last minute of the Pre-Noise time point was
utilized to represent the behavior and HRV of dogs during that
time point, which served as a reference of their normal behavior
prior to the fireworks track starting. Additionally, only the first
minute of the Noise time point was utilized to represent the dogs’

Frontiers in Veterinary Science | www.frontiersin.org

Parameter

Definition

HR

Heart rate, bpm

AVNN

Mean beat-to-beat intervals, ms

SDNN

Standard deviation of beat-to-beat intervals, ms

RMSSD

Square root of the mean squared difference of
successive RRs or inter-beat intervals, ms

pNN50

Percentage of successive RR intervals that differ by
more than 50 ms, %

LF

Peak frequency of the low-frequency band
(0.04–0.15 Hz)

HF

Peak frequency of the high-frequency band
(0.15–0.40 Hz)

LF/HF

Ratio of LF-to-HF

behavior and HRV during that time point in order to assess the
dogs’ initial reaction to the fireworks tract.

Data Collection
Consumption of food and treats, consistency of stool, frequency
of elimination, activity during exercise, mucus membrane color,
and other indicators of general health status were monitored
twice daily by research personnel. Evidence of any adverse
event—defined as any symptom occurrence that would not
be expected in normal dogs—was also monitored. However,
no adverse events were observed in any dogs following the
administration of CBD treats during this study.
On the day of each fireworks test, blood samples (5 mL)
were collected via jugular or cephalic venipuncture 1 h prior to
testing, immediately after testing (5–10 min after cessation of
noise exposure), and again 1 h post testing for cortisol and CBD
analysis. Blood samples were collected into EDTA plasma tubes,
centrifuged at 1,645 × g, and stored at −80◦ C for later analysis.
Plasma samples were analyzed in duplicate for cortisol using
a commercial radioimmunoassay kit (MP Biomedicals, LLC,
Solon, OH). The sensitivity reported for the radioimmunoassay
was 1.7 ng/mL, and the intra- and inter-assay coefficients of
variation were 5.3–8.9% and 7.5–9.3%, respectively.
Polar H10 (Polar Electro Inc., Bethpage, NY) heart rate
sensors were used for the collection of heart rate (HR) and heart
rate variability (HRV) parameters via Bluetooth connection to
an iPhone app (Heart Rate Variability Logger, Marco Altini).
Parameters measured are defined in Table 2. In general, HR
will increase and HRV will decrease in response to stressful
stimuli as a result of an increase in sympathetic nervous
system activity (25). Thus, an effective treatment would be
expected to decrease HR and increase HRV, indicating higher
parasympathetic activity. Just prior to the open field and
fireworks tests, the heart rate monitor bands were placed around
the chest of the dogs immediately behind the front legs, with the
rubberized surface placed ventrally immediately behind the left
front leg. Electrode gel was applied liberally to the rubberized
surface of the transmitter band to promote conductivity. Due to
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duration of fearful behaviors such as panting, cowering, and tail
tuck were expected to increase during the fireworks test. Thus,
an effective treatment was expected to decrease the duration
of such fearful behaviors. Behaviors in different behavioral
categories (i.e., Movement vs. Tail Posture) were not mutually
exclusive, whereas behaviors within a behavioral category were
mutually exclusive.

TABLE 3 | Ethogram of behaviors tracked by a single trained observer blinded to
treatments using The Observer XT (Noldus Information Technology Inc.,
Leesburg, VA).
Behavioral category

Behavior

Definition used

Movement

Inactive

Standing still, sitting, or
laying down

Cowering

Sudden cessation of
movement in response to a
stimulus

Eyes

Ears

Tail posture

Muzzle

Pacing

Frantically moving back and
forth, restlessness

Destruction

Scratching or chewing at
room furnishings

Facing door

Eyes are focused on the
door of the room

Glancing around

Eyes are shifting back and
forth, possibly looking for
the source of a sound

Other

Eyes are focused on
something else in the room

Ears relaxed

Ears are held in natural
position

Ears erect

Ears raised in response to
stimulus

Ears moving

Ears moving back and forth

Tail relaxed

Tail is not rigid and is lower
than the top of the body

Tail stiff

Tail is rigid and horizontal

Tail wagging

Tail is wagging back and
forth

Tail tucked

Tail is tucked between hind
legs

Barking

Emitting a short, loud sound

Whining

Emitting a long, high pitch
sound, often repeated

Panting

Mouth open wide with
tongue protruding while
breathing heavily

Licking

Using the tongue on own
body or another object

Yawning

Opening the mouth wide
and inhaling

Biting

Using teeth on the door or
object

Statistical Analysis
The normality of data distribution was tested using the
UNIVARIATE procedure in SAS (SAS Institute, Cary, NC) on
the residual of the data. In instances where data did not meet
normality assumptions, statistical analysis was performed on
the natural logarithm transformation of the data. However,
data were then back transformed for reporting purposes. The
standard error of the back transformed data was calculated
from the confidence limits of the transformed data as follows:
SEM = (back-transformed upper limit–back-transformed lower
limit)/3.92. The denominator relates to the Z-value of a 95%
confidence interval (± 1.96). Cowering, pacing, destruction, tail
wagging, tail tucked, and all muzzle behaviors could not be
analyzed due to insufficient occurrences that prevented data
from meeting normality assumptions. With the exception of HR,
pNN50, and HF, parameters were not normally distributed and
were analyzed using the natural logarithm of the data.
Blood cortisol was then analyzed using the MIXED procedure
in SAS including the fixed effects of CBD, trazodone, period
(Weeks 1–4), time (−60, 0, and 60 min), the interaction of CBD
and trazodone, and the interaction of CBD by trazodone by time.
Random effects included square and dog nested within square
and repeated effect of time. All behavioral and HRV data from the
1-min immediately prior to (Pre-Noise) and the first min of the
noise-induced fear response test (Noise) were also analyzed using
the MIXED procedure in SAS including the fixed effects of CBD,
trazodone, period (Weeks 1–4), time (Pre-Noise and Noise), and
all accompanying interactions. Random effects included square
and dog nested within square and repeated effect of time. Effects
were considered significant when P ≤ 0.05 and considered a
tendency when P ≤ 0.10.

RESULTS
Blood Cortisol
There was an overall effect of period on blood cortisol (P =
0.024). Blood cortisol was reduced in period 1 compared to both
periods 3 and 4 (P = 0.003 and 0.003, respectively), but was
similar across all other periods (P > 0.05). Blood cortisol was
unaffected by time of collection and CBD (P = 0.189, 0.104,
respectively). Similarly, neither the CBD x trazodone, time ×
CBD, time × trazodone, nor the time × CBD × trazodone
interactions affected blood cortisol (P = 0.238 0.772, 0.667, and
0.812, respectively). However, trazodone lowered blood cortisol
concentrations (Figure 1; P < 0.0001).

all dogs having short hair and the use of electrode gel, dogs did
not have to be shaved to promote conductivity.
Two cameras mounted ∼2 m from the floor on opposite
corners of the testing room continuously recorded all video
and audio data for each test. The duration of behaviors given
in Table 3 were logged by a single trained observer who was
blinded to treatments using The Observer XT software (Noldus
Information Technology Inc., Leesburg, VA). Three of the dogs
included on the study had docked tails, and as such had no data
on tail posture. The behaviors assessed were selected based on
behavioral measures used in previous work evaluating canine
anxiety and fear (5, 23, 26). Based on these previous studies,
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Heart Rate and Heart Rate Variability
There was a period effect on both HR and AVNN (Table 4; P
= 0.005 and 0.046, respectively). Heart rate in period 4 tended
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FIGURE 1 | Cortisol concentration (ng/mL) for each treatment (n = 16), back transformed after analysis. Error bars represent the standard error of the treatment mean
(SEM), which was calculated from the back-transformed confidence interval for each treatment: SEM = (upper limit—lower limit)/3.92. Due to lack of effect of time (P
= 0.189) and any interactions with time (P > 0.05), all time points (Pre-Noise and Noise) have been combined. Trazodone treatment reduced cortisol concentration (P
< 0.001), whereas there was no effect of CBD (P = 0.104) nor the CBD by trazodone interaction (P = 0.238).

TABLE 4 | Effect of trazodone (T), CBD (C), CBD by trazodone (C* T) interaction, time (Pre-Noise and Noise), CBD by trazodone by time (C* T* Time) interaction, and period
on mean heart rate (HR) and heart rate variability (HRV) parameters for 1-min immediately prior to (Pre-Noise) and the first minute (Noise) of the noise-induced fear
response tests administered after each 7-d treatment period.
Parameter

SE1

Treatment
Control

Trazodone (T)

CBD (C)

T+C

HR, bpm

118.03

118.02

124.20

124.07

AVNN, ms

555.96

539.85

539.42

517.50

SDNN, ms

108.16

102.96

106.54

RMSSD, ms

100.35

89.28

91.70

P-value
Trazodone

CBD

C*T

Time

C*T*Time

Period

10.968

0.985

0.093

0.987

<.001

0.637

0.005

25.988

0.276

0.266

0.850

0.040

0.807

0.046

88.18

7.129

0.200

0.359

0.450

0.977

0.419

0.695

69.71

12.649

0.130

0.189

0.538

0.366

0.654

0.538
0.306

pNN50, %

41.19

36.99

36.88

33.73

5.774

0.180

0.168

0.847

0.032

0.773

LF, Hz

0.090

0.062

0.050

0.048

0.0071

0.188

0.011

0.315

0.010

0.273

0.533

HF, Hz

0.142a

0.076b

0.059b

0.068b

0.0221

0.205

0.022

0.071

0.036

0.853

0.481

0.595

0.126

0.183

0.053

0.039

0.908

LF/HF Ratio
Pre-Noise
Noise

0.729

0.803

0.711

0.540

0.1052

0.651a,b

0.992a*

0.907a,b

0.607b

0.1402

0.808a

0.615a

0.515a

0.474a*

0.1461

1 The standard error (SE) of the back transformed data was calculated from the confidence limits of the transformed data as follows: SE = (back-transformed upper limit—backtransformed lower limit)/3.92.
ab* Within rows, values with different letters differ at P ≤ 0.05 and asterisks indicate a trend at P < 0.10.
Treatment T+C indicates the combination treatment of CBD and trazodone. With the exception of HR, pNN50, and HF, parameters were not normally distributed and were analyzed
using the natural logarithm. Data were back transformed for reporting purposes. In the event of a treatment by time interaction, parameters are given as their treatment mean within
each time point (Pre-Noise and Noise).

With the exception of SDNN and RMSSD, HR and all other
HRV variables were affected by the time point (Pre-Noise vs.
Noise) (Table 4; P < 0.05). HR was lower during the Pre-Noise
time point compared to the Noise time point (P < 0.001), while
HRV parameters affected by time—AVNN, pNN50, LF, and HF—
were all higher during the Pre-Noise time point than the Noise
time point (P < 0.05). The LF/HF ratio tended (P = 0.053) to

to be lower than in period 1 (P = 0.075) and was lower than in
periods 2 and 3 (P = 0.004 and 0.001, respectively). Heart rate was
similar between periods 1, 2, and 3 (P > 0.05). The mean beat-tobeat intervals (AVNN) was increased in period 4 compared to all
other periods (P = 0.021, 0.018, and 0.030, respectively), but was
similar between all other periods (P > 0.05). All other HR and
HRV variables were unaffected by period (P > 0.05).
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fearful behavioral response. However, the behaviors Glancing
Around and Ears Moving could be considered a normal response
to hearing a loud noise and may not necessarily indicate a
fearful response to the noise. However, since the common
fearful behaviors measured—cowering, pacing, vocalizations,
etc.—could not be analyzed due to insufficient occurrences, it is
difficult to determine if the fireworks test was severe enough to
generate a fearful response.

be higher in the Pre-Noise time point compared to the Noise
time point.
CBD tended to increase overall HR (Table 4; P = 0.093), and
decreased LF regardless of time point (P = 0.011). All treatments
reduced HF compared to control (P < 0.05). AVNN, SDNN,
RMSSD, and pNN50 were unaltered by CBD and trazodone (P
< 0.05). No HRV variables were affected by the CBD by time
nor the trazodone by time interaction (P > 0.05). The CBD by
trazodone by time interaction influenced the LF/HF ratio (P =
0.039). During the Pre-Noise time point, trazodone tended (P
= 0.061) to increase the LF/HF ratio compared to control and
increased the LF/HF ratio compared to the combination of CBD
and trazodone (P = 0.038). During the Noise time point, the
combination of CBD and trazodone tended (P = 0.083) to reduce
the LF/HF ratio compared to control.

DISCUSSION
Since the passage of the Agriculture Improvement Act of 2018,
which removed industrial hemp from the Controlled Substances
Act and removed CBD from the Schedule I drug list, the
market for industrial hemp-derived CBD has been able to expand
considerably (27). Just 1 year after the act passed, the market
was estimated to be $1.2 billion and is expected to grow to over
$10 billion by 2024 (28). Much of this growth can be attributed
to public perception of the supposed health benefits of CBD,
including analgesic, antioxidant, anti-inflammatory, and antianxiety effects. However, despite general public opinion that CBD
is a safe and effective treatment for these conditions, the lack
of scientific clarity on the safety, dosage, and efficacy of CBD
makes it critical for continued research in both humans and
companion animals.
The present study is one of the first to describe the effect of
CBD on the fear and anxiety response of dogs. The fear-response
test was developed and validated by Araujo et al. (22), in which
dogs were placed in the test room for 9 min and a thunderstorm
track was played from 3 to 6 min. A modified version of this test
was used in the current study, with a fireworks track being used
instead of a thunderstorm track as previous literature has shown
a greater percentage of dogs to be fearful of fireworks than of
thunderstorms (1). Additionally, because Araujo et al. (22) saw
no behavioral differences during the “after thunder” time period,

Behavior
There were no period effects on any behavioral variables (Table 5;
P > 0.05). With the exception of Facing Door and Tail Relaxed, all
other behaviors were affected by time point (Pre-Noise vs. Noise;
P < 0.05). During the Noise time point, duration of inactivity
(P = 0.011), Glancing Around (P < 0.001), and Ears Moving (P
< 0.001) were increased compared to their duration during the
Pre-Noise time point. Conversely, the duration of Other Eyes,
Ears Relaxed, Ears Erect, and Tail Stiff were reduced during the
Noise time point compared to the Pre-Noise time point (P <
0.05). Across both time points, dogs fed CBD tended (P = 0.072)
to spend less time focused on something in the room (Other
Eyes). Conversely, trazodone increased overall duration of Other
Eyes (P = 0.044) and time spent with Tail Relaxed (P = 0.001),
but CBD did not alter tail posture (P = 0.753). No behavioral
variables were affected by the CBD by time nor the trazodone by
time interaction (P > 0.05).
These changes between the Pre-Noise and Noise time points
may indicate that the fireworks test generated the desired

TABLE 5 | Effect of trazodone (T), CBD (C), CBD by trazodone interaction (C* T), time (Pre-Noise and Noise), CBD by trazodone by time interaction (C* T* Time), and period
on the duration of behavioral parameters (s) for 1-min immediately prior to (Pre-Noise) and the first minute (Noise) of the noise-induced fear response tests administered
after each 7-d treatment period.
Parameter, s

SE1

Treatment
Control

Trazodone (T)

CBD (C)

T+C

P-value
Trazodone

CBD

C*T

Time

C*T*Time

Period

Inactive

55.35

56.33

55.21

56.26

1.214

0.329

0.918

0.971

0.011

0.092

0.993

Facing door

37.45

33.90

34.96

37.70

4.198

0.872

0.796

0.217

0.561

0.556

0.786

Glancing around

16.90

15.65

17.93

15.91

3.460

0.396

0.736

0.841

<.001

0.142

0.819

Other eyes

5.10

13.33

4.10

5.48

1.885

0.044

0.072

0.182

<.001

0.469

0.792

Ears relaxed

11.37

7.76

12.35

11.43

4.913

0.179

0.168

0.422

<.001

0.868

0.567

Ears erect

29.33

34.29

29.93

29.80

5.614

0.304

0.408

0.279

<.001

0.747

0.982

Ears moving

19.25

17.79

17.20

18.78

2.076

0.970

0.742

0.351

<.001

0.457

0.493

Tail relaxed

37.90

49.86

38.93

50.96

4.857

0.001

0.753

0.992

0.611

0.898

0.990

Tail stiff

18.45

5.55

16.39

6.65

4.582

0.002

0.887

0.644

0.010

0.757

0.896

Treatment T+C indicates the combination treatment of CBD and trazodone. 1 The standard error (SE) of the back transformed data was calculated from the confidence limits of the
transformed data as follows: SE = (back-transformed upper limit—back-transformed lower limit)/3.92.
Parameters were not normally distributed and were analyzed using the natural logarithm. Data were back transformed for reporting purposes.
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between 1,400 and 1,600 h. While blood cortisol concentrations
in samples taken from 1,300 to 1,600 h were lower than those
taken between 1,000 and 1,300 h (31), that effect was not seen
in this study. This could indicate that the noise-induced fear
response test did in fact affect blood cortisol concentrations,
maintaining the elevated levels through the afternoon rather than
the normal drop expected from the circadian rhythm of the
hormone. These results warrant further investigation, and future
work should consider administering the noise test earlier in the
day to account for possible influence of the circadian rhythm
of cortisol.
In humans, trazodone has been shown to decrease plasma
cortisol concentrations compared with placebo and is commonly
prescribed for the treatment of anxiety, depression, and to
facilitate sleep (7, 32). While trazodone is not currently labeled
for use in dogs, off-label use of trazodone is common for
the treatment of anxiety disorders as well as to reduce the
agitation and distress associated with post-surgery confinement
and reduced exercise (33, 34). In this experiment, treatment with
trazodone lowered blood cortisol concentrations compared to all
other treatments. On the other hand, CBD did not alter plasma
cortisol concentrations compared to control in this experiment.
In humans, CBD administration has been shown to attenuate
the cortisol decrease associated with the circadian rhythm of the
hormone (35, 36). While other anxiolytic supplements seem to
reduce anxiety in dogs at least in part by reducing the cortisol
response to stressors (9), the results of this study may suggest
that CBD does not exert an anti-anxiety effect by lowering blood
cortisol concentrations. However, Hurd et al. (37) demonstrated
a decrease in salivary cortisol when CBD was dosed to humans at
∼5 and 10 mg/kg BW, which may indicate that the CBD dosage
selected for this study (1.4 mg/kg BW) was too low to exert an
effect on cortisol.
Another possibility is that CBD was administered too early
in the day of the fireworks test. Recent work with other oral
CBD products with similar dosages to this study demonstrated
the time of maximum CBD concentration to be around 1.5 h
after administration and the half-life of elimination to be between
1 and 4 h (16, 38, 39). However, at the time this study was
completed (July 2018), these works on CBD pharmacokinetics
had not yet been published, and earlier literature (24) reported
much longer half-life for IV administration of CBD. This resulted
in CBD treats being administered between 4 and 6 h prior to the
test in this study. In the future, it may be necessary to administer
treatments within 2 h of the noise test in order for CBD to have
the greatest effect. This was accounted for in the administration
of trazodone, as Jay et al. (21) reported that the same dose of oral
trazodone had a mean half-life of 166 min in dogs.
Even if CBD was administered too early to exert an anxiolytic
effect, CBD did appear to inhibit the ability of trazodone to lower
blood cortisol in the combination treatment compared with
trazodone alone. This observation may support previous work
that shows CBD to be a potent inhibitor of the cytochrome P450
family of enzymes, which is responsible for the metabolism of
trazodone to its active metabolite, m-chlorophenylpiperazine, in
the liver (40, 41). Several studies have highlighted these potential
CBD-drug interactions as well as the lack of information

the test for this study was shortened to 6 min, ending immediately
after the fireworks track ended. This allowed for the immediate
post-test blood sample collection to be obtained within 10 min of
the end of the fireworks test.
If cortisol concentrations had decreased with each subsequent
period of the experiment, it would have been an indication that
the dogs were adapting to the sound stimulus. While there was
a period effect on cortisol, it was due to cortisol in periods 3
and 4 being increased compared to period 1. This may indicate
a heightened response to the sound stimulus upon repeated
exposure, which suggests that the dogs were being conditioned to
be stressed in the testing room despite being placed in the room
on non-testing days to avoid such conditioning. The potential for
conditioned place aversion is a limitation of the crossover design
used in this study. It may be beneficial in future work to either
include washout periods or utilize a different design to reduce
the number of tests administered to each dog to prevent this
conditioning; however, the latter would require a larger sample
size than is needed when using a Latin Square design.
The lack of a time effect on blood cortisol concentration was
also unexpected. It is possible that cortisol concentrations did
not change because the fireworks test may not have produced
a sufficient change in fear or stress in these dogs. However,
Landsberg et al. (9) demonstrated that the use of a thunderstorm
noise-induced fear response test—also averaging 90 dB—resulted
in a time-dependent change in blood cortisol, with higher
concentrations 5 min post-test compared to 1 h pre- and posttest samples. This time effect was not replicated in this study.
Instead, cortisol concentrations decreased at each subsequent
timepoint, though not enough to produce an overall effect of
time. Other studies have also demonstrated that blood and
saliva cortisol concentrations peak between 5 and 20 min after
noise exposure and begin to decline as early as 30 min postexposure (23, 29, 30). For this study, while the blood sample
taken immediately after the test was taken within this window,
it is possible that cortisol levels had not yet peaked after noise
exposure. It would be beneficial in future work to take additional
blood samples throughout the first hour after noise exposure to
better show cortisol changes after noise exposure. Alternatively,
it is also possible that the lack of time effect on cortisol may
have been due to elevated initial stress due to the use of shelter
animals. Franzini de Souza et al. (23) demonstrated differences
in endocrine and behavioral responses between laboratory and
companion dogs in response to sound stimuli. While shelter
animals were not represented in that study, it is possible that
increased stress from the shelter environment, transport, and new
environment could impact cortisol concentrations and warrants
further investigation.
It is also possible that the time of testing influenced
cortisol concentrations. Kolevská et al. (31) showed that dogs
not undergoing an exercise regimen had the highest blood
cortisol concentrations between 1,000 and 1,300 h and the lowest
concentrations between 1,600 and 1,900 h. A similar pattern was
seen in this experiment, with the highest cortisol concentrations
at the 60-min pre-test sample, which would have been taken
between 1,200 and 1,400 h, and the lowest concentrations at the
60-min post-test sample period, which would have been taken
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and has been demonstrated in dogs exposed to sound stimuli
(23, 29, 57). In this study, however, the LF/HF ratio tended to
be reduced during the fireworks track compared to the Pre-Noise
time point. This, combined with the reduction in LF, may indicate
that the fireworks track was not sufficient to cause a fearful or
stress response.
Additionally, the fireworks tract did not alter SDNN nor
RMSSD in this study. The standard deviation of interbeatintervals (SDNN) measures how interbeat-intervals change over
time and has been shown to be reduced by stress (25, 52).
As such, SDNN is generally measured over a 24 h collection
period, though short-term periods have also been used to evaluate
short-term variability (58, 59). The RMSSD reflects beat-to-beat
variance and is used to estimate vagal mediated changes in HRV,
which reflects self-regulatory capacity (56). Reduced RMSSD has
been associated with smoking, high LDL cholesterol, and work
stress in humans and has been shown to be reduced in soundsensitive dogs in response to sound exposure (29, 55). As some
of the findings of this study concur with previous work and
other results conflict with what was expected upon exposure to
fireworks, it is possible that the fireworks test was not successful
in generating the desired fearful response. However, some of this
conflicting evidence may be a result of the ultra-short time frame
used for recording HRV, particularly for some variables that are
more commonly measured over longer time periods. Future work
should consider recording HRV over longer time frames in order
to better assess changes. Only HR and AVNN were affected by the
period of the experiment, where HR was reduced in period 4 and
AVNN was increased in period 4 compared to all other periods.
This may suggest that the dogs were acclimating to the fireworks
stimulus, a limitation to this study design. Future work should
consider either washout periods or a study design that does not
require multiple noise-induced fear response tests in order to
avoid this problem.
To our knowledge, no work has been done to evaluate the
effect of CBD or trazodone administration on HRV in dogs,
though there is some evidence that CBD may improve HRV in
healthy humans (60). Since an increase in stress and anxiety due
to sound stimuli has been shown to increase HR, LF, and the
LF/HF ratio while decreasing RMSSD, and HF (23, 29, 57), it
was expected that both CBD and trazodone would attenuate these
changes. In contrast to these expectations, both LF and HF were
decreased by CBD in this study compared to control. Conversely,
CBD tended to increase HR, while SDNN, RMSSD, and pNN50
were unaffected by treatment. While the reduction in LF would
indicate that CBD attenuated the increase in cardiac sympathetic
modulation, the increase in HR and decrease in HF suggest
the opposite. Trazodone, again in contradiction to expectations,
reduced overall HF in this study, tended to increase the LF/HF
ratio during the Pre-Noise time point, and did not affect any
other HRV parameters. The combination of CBD and trazodone
also reduced HF compared to control and tended to reduce the
LF/HF ratio compared to all other treatments during the Noise
time point when the fireworks track was playing. The lack of
effect on other HRV parameters such as SDNN and RMSSD may
be due to the fireworks track not producing a change in these
variables rather than a lack of treatment effect. These conflicting

regarding CBD doses that can be deemed safe for use—whether
administered alone or in combination with other medications
(42–45). The potential interaction between CBD and trazodone
demonstrated in this study lends support to these concerns.
While there has been some work investigating specific CBDdrug interactions (46), it may be inadvisable to administer CBD
concomitantly with other products or medications until these
interactions are more fully elucidated.
In agreement with previous work in both dogs and other
species, oral CBD administration in this experiment was welltolerated. No gastrointestinal or constitutional adverse events
were observed in dogs receiving CBD during this study.
Additionally, food consumption and body weight remained
consistent throughout the experiment. However, other studies
evaluating the safety of oral CBD administration in dogs have
reported the potential for adverse events, including lethargy,
gastrointestinal issues such as vomiting or diarrhea, and
hematological changes such as increases in liver enzymes (16, 39,
47, 48). However, aside from initial bloodwork evaluated upon
animal intake from the shelter, hematological changes were not
evaluated during this experiment. As increases in liver enzymes
may be indicative of altered liver function, the potential effects of
oral CBD administration on clinical chemistry parameters should
be monitored in future work.
Heart rate variability has been used as a measure of stress
and anxiety in a number of animal species, including dogs.
In particular, considerable work has been done using HRV
as an indicator of canine fear and anxiety in response to
stressful stimuli, in which HRV generally decreases and HR
increases when animals are under stress, indicating impaired
parasympathetic function and autonomic nervous system
dysregulation (49–51). The results of this study concur, showing
increased HR and decreased HRV—AVNN, pNN50, LF, and
HF—during the fireworks stimulus compared to the Pre-Noise
time point when no sound was played. As AVNN represents
the interval between heart beats, the decrease in AVNN was
expected alongside the increase in HR during the fireworks
stimulus. The pNN50 is thought to relate to parasympathetic
activity and was also expected to decrease with increased stress
from the fireworks stimulus (25, 52). The low frequency band
(LF) mainly reflects baroreceptor activity in the heart while
at rest, but can be generated by parasympathetic, sympathetic,
or baroreceptor activity depending on the situation. Unlike
other HRV parameters, the LF band is expected to increase
with stress as an increase in baroreceptor activity would be
expected to accompany a rise in blood pressure (25, 53). This
was not replicated in this study, where LF actually decreased
during the fireworks stimuli. The high frequency band (HF), or
respiratory band, corresponds to heart rate variations related to
the respiratory cycle. Unlike LF, HF only reflects parasympathetic
activity, and lower HF is correlated with stress and anxiety
(54, 55). Because LF can be influenced by both sympathetic
and parasympathetic activity while HF is only produced by
parasympathetic activity, the LF/HF ratio has been used as a
way to estimate sympathetic vs. parasympathetic activity (56). An
increased LF/HF ratio is thought to indicate higher sympathetic
drive, which would be expected when exposed to stressful stimuli
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in order to produce anxiolytic effects. Future investigation into
these possibilities is warranted.
While there was no period effect on any behavioral variables,
the lack of behavioral response to treatment could also have been
due to acclimation of some of the animals to the firework track.
While dogs were selected for inclusion into the study based on
their reaction to the baseline noise-induced fear response test, it is
possible that the weekly exposure to the stimulus diminished the
reaction of some of the dogs during the later tests. This hypothesis
is supported by the effect of period on other variables measured
in this study, including plasma cortisol, HR, and AVNN. This
highlights an important limitation of this study design, where
time constraints prevented washout periods. To avoid this issue
in future work, dogs could be blocked by their reaction to the
baseline test and assigned to just one treatment for the duration
of the study. This would eliminate the need for multiple firework
tests and would allow baseline and treatment tests to be spaced
out over time but would also require a much larger sample size.
However, considering the high level of variability in behavioral
responses to the fireworks test, it would be difficult to ensure
even distribution of dogs even with blocking. If feasible, it would
be ideal to utilize the crossover design with longer washout
periods to minimize the potential for acclimation to the stressful
stimulus. The variability in behavioral responses also makes it
difficult to quantify different fear responses. Several of the most
common fearful behaviors (shaking, cowering, panting, etc.)
were measured, but could not be analyzed due to insufficient
occurrences, which may be accounted for in future work by
aggregating such behaviors together into one behavioral category.
The inclusion of a non-fearful control group should also be
considered for future work as it would allow for better evaluation
of changes in fearful behaviors in reactive dogs.

results warrant further investigation, particularly considering the
lack of information available regarding the effects of both CBD
and trazodone on HRV in dogs.
When the fireworks track started, there was a visible change
in the demeanor of the dogs compared to both the open field test
and the first 3-min block of the noise-induced fear response tests
(Pre-Noise). While this may indicate that the fireworks track was
able to generate the desired behavioral response, it is also possible
that the change in behavior was a result of the dogs’ interest in the
noise rather than a fearful response. However, the considerable
variability in the type of observed responses makes it difficult to
elucidate whether the change was due to fear or if it was just
a reflexive response. The predominant response was a decrease
in activity, which may or may not have been accompanied by
a variety of other behaviors, such as a tucked tail, shaking,
or nervous vocalizations like whining. These fearful behaviors
would have been a better representation of the behavior changes
due to the fireworks test as they have been used to evaluate such
changes in other work (9, 23, 29, 57). However, these behaviors
occurred too infrequently in this study to allow for statistical
analysis. This may be indicative of a lack of behavioral response
to the fireworks test. However, as all dogs were selected for this
experiment based on the presentation of one or more fearful
behaviors during baseline testing, this may simply highlight
the variation in behavioral responses to sound exposure. Other
anxiolytic supplements and medications have been shown to
increase activity or distance traveled using this model (9, 22);
however, neither CBD nor trazodone treatment changed activity
compared to control. This is particularly surprising for the
treatment groups receiving trazodone, which has previously been
shown to visibly reduce behaviors associated with a number of
stressful situations (34, 61, 62). However, several of these studies
relied on owner-completed surveys rather than objective data to
assess effectiveness.
In contrast, CBD has been shown to reduce anxious behaviors
in mouse, rat, and human models, but at this time there is
little to no literature regarding its effect on canine behavior. In
mouse and rat models, responses to threatening or unpleasant
stimuli were assessed by several methods, including the elevated
plus-maze, Vogel-conflict test, contextual fear conditioning, and
elevated T maze (63–65). The use of these models has shown that
intraperitoneal administration of CBD in doses ranging from 1 to
20 mg/kg produced anxiolytic effects with some responses being
dose-dependent (18, 19). Though different models of anxiety
were used in rodents, this may indicate that a higher dose is
necessary to produce the desired behavioral changes associated
with reduced stress and anxiety, particularly if dosed orally due
to the considerable first-pass effect on CBD in the liver (24, 66).
Future research should investigate the effect of higher dosage
of CBD for dogs above the dose tested in this study. Another
important consideration is the time of CBD administration prior
to noise exposure. As previously mentioned, oral CBD has been
shown to have a half-life of <4 h (16, 38, 39), but CBD treats in
this experiment were dosed between 4 and 6 h of testing. Thus, it
is possible that the dose used in this study would be sufficient to
generate an anxiolytic effect if dosed closer to the fireworks test.
Alternatively, CBD may need to be dosed for longer than 7 days
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CONCLUSIONS
The results of the current study do not provide strong support
of an anxiolytic effect of CBD in dogs when supplemented
at 1.4 mg CBD/kg BW/d. Trazodone, but not CBD, decreased
plasma cortisol concentration. When combined with trazodone,
CBD appeared to attenuate the effects of trazodone on plasma
cortisol. Cannabidiol decreased LF and HF, tended to increase
HR, and tended to decrease duration of Other Eyes. Conversely,
trazodone increased duration of Other Eyes, increased time spent
with tail relaxed, reduced HF, increased the LF/HF ratio.
It would be beneficial in future studies to use increasing doses
of CBD to clarify any potential anxiolytic effect, if present, and the
dose necessary to elicit that effect. This study demonstrates the
considerable variation in canine anxiety behaviors, which makes
it difficult to accurately measure the response to treatments.
It may be inadvisable to administer CBD concomitantly with
other products or medications as the results from this study
highlight potential drug interactions associated with CBD use.
Considering the increased interest of CBD use in companion
animals, continued research is essential to understanding the
mechanisms by which CBD may exert anxiolytic effects as
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well as possible risks, like drug interactions, associated with
CBD administration.
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